Regarding VEGF family members, a study conducted on children with ALL, including nine patients with confirmed central nervous system localisation (CNSL), demonstrated that the BM levels of VEGF-A at the beginning and in further therapy stages were similar and that the reduction of leukaemic blasts in BM did not lead to diminished VEGF-A levels. The gene discussed is VEGFA; the disease is acute lymphoblastic leukemia.